Deal to progress Alzheimer's vaccine

AFFiRiS GmbH has granted GlaxoSmithKline Biologicals S.A. (GSK) exclusive rights to develop and commercialise its Alzheimer's disease vaccine candidates. Two are currently in Phase I clinical development, and others are in preclinical development.

The AFFiRiS AFFiTOPE technology allows the design of proteins with very specific binding characteristics that are ideally suited for the development of vaccines against disease-causing ‘rogue’ human proteins, such as beta-amyloid – central to Alzheimer’s disease pathology.
AFFiRiS GmbH (www.affiris.com) develops peptide-based vaccines to combat Alzheimer’s disease, atherosclerosis and other diseases. The company has established platform technologies and a worldwide patent portfolio covering their vaccine candidates.

20.11.2008

News • Standardized assessment criteria

Lost in translation: ICU experts call for universal severity score

Current scores to assess the severity of illness in ICU patients often fail in international contexts. Researchers now call for a global scoring system based on universally available data.

Product • Slide scanner system

Hamamatsu NanoZoomer® S540MD

The NanoZoomer S540MD by Hamamatsu is engineered with the lab in mind for a seamless workflow. Featuring compatibility with staining racks, fast slide scanning, exceptional image quality, and an…